A Study to Evaluate Impact of Efanesoctocog Alfa on Long-term Joint Health in Participants With Hemophilia A
NCT05911763
·
clinicaltrials.gov ↗
ACTIVE_NOT_RECRUITING
Status
200
Enrollment
INDUSTRY
Sponsor class
Conditions
Hemophilia A
Interventions
DRUG:
Efanesoctocog Alfa BIVV001
Sponsor
Sanofi